ValueAct Capital opposed to Chimera Investment's proposed 'massively dilutive' offering

By Lisa Kerner

Charlotte, N.C., Oct. 21 - Chimera Investment Corp. shareholder ValueAct Capital said the company's proposed "massively dilutive offering of 250 million new Chimera shares at a significant discount to current book value is misguided."

In an Oct. 21 letter to Chimera's board of directors, ValueAct urged the board and management to rethink the timing and size of the offering.

According to ValueAct, an 11.6% shareholder, Chimera is attempting to sell 250 million shares on a base of 36 million "at the worst possible time to be a seller."

Chimera is a New York-based real estate investment trust.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.